JP6617029B2 - ジアザビシクロオクタン誘導体の結晶とその製造法 - Google Patents

ジアザビシクロオクタン誘導体の結晶とその製造法 Download PDF

Info

Publication number
JP6617029B2
JP6617029B2 JP2015541603A JP2015541603A JP6617029B2 JP 6617029 B2 JP6617029 B2 JP 6617029B2 JP 2015541603 A JP2015541603 A JP 2015541603A JP 2015541603 A JP2015541603 A JP 2015541603A JP 6617029 B2 JP6617029 B2 JP 6617029B2
Authority
JP
Japan
Prior art keywords
tert
vii
formula
amino
diazabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015541603A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2015053297A1 (ja
Inventor
阿部  隆夫
剛 古内
儀晃 坂巻
那佳子 三橋
由美子 齋藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Publication of JPWO2015053297A1 publication Critical patent/JPWO2015053297A1/ja
Application granted granted Critical
Publication of JP6617029B2 publication Critical patent/JP6617029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015541603A 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法 Active JP6617029B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019171587A Division JP6995810B2 (ja) 2013-10-08 2019-09-20 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (2)

Publication Number Publication Date
JPWO2015053297A1 JPWO2015053297A1 (ja) 2017-03-09
JP6617029B2 true JP6617029B2 (ja) 2019-12-04

Family

ID=52813113

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015541603A Active JP6617029B2 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法
JP2019171587A Active JP6995810B2 (ja) 2013-10-08 2019-09-20 ジアザビシクロオクタン誘導体の結晶とその製造法
JP2021145422A Active JP7182677B2 (ja) 2013-10-08 2021-09-07 ジアザビシクロオクタン誘導体の結晶とその製造法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019171587A Active JP6995810B2 (ja) 2013-10-08 2019-09-20 ジアザビシクロオクタン誘導体の結晶とその製造法
JP2021145422A Active JP7182677B2 (ja) 2013-10-08 2021-09-07 ジアザビシクロオクタン誘導体の結晶とその製造法

Country Status (22)

Country Link
US (5) US10131665B2 (cg-RX-API-DMAC7.html)
EP (4) EP3613740A1 (cg-RX-API-DMAC7.html)
JP (3) JP6617029B2 (cg-RX-API-DMAC7.html)
KR (2) KR102388529B1 (cg-RX-API-DMAC7.html)
CN (2) CN105612159A (cg-RX-API-DMAC7.html)
AR (4) AR097971A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014332960B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022016622B1 (cg-RX-API-DMAC7.html)
CA (2) CA3110803C (cg-RX-API-DMAC7.html)
DK (1) DK3067355T3 (cg-RX-API-DMAC7.html)
ES (2) ES2901198T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219479A1 (cg-RX-API-DMAC7.html)
HU (1) HUE051925T2 (cg-RX-API-DMAC7.html)
IL (2) IL244969B (cg-RX-API-DMAC7.html)
MX (2) MX383661B (cg-RX-API-DMAC7.html)
MY (1) MY199066A (cg-RX-API-DMAC7.html)
NZ (5) NZ719568A (cg-RX-API-DMAC7.html)
RU (1) RU2695219C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201602723RA (cg-RX-API-DMAC7.html)
TW (1) TWI673269B (cg-RX-API-DMAC7.html)
WO (1) WO2015053297A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602054B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
SG11201704576SA (en) * 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
EP3687504B1 (en) 2017-09-27 2024-11-27 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
WO2022014395A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (cg-RX-API-DMAC7.html) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (cg-RX-API-DMAC7.html) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) * 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8829191B2 (en) * 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) * 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
IN2014MU01192A (cg-RX-API-DMAC7.html) 2014-03-29 2015-10-02 Wockhardt Ltd
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation

Also Published As

Publication number Publication date
CA2926071A1 (en) 2015-04-16
RU2016116501A (ru) 2017-11-15
EP3067355A1 (en) 2016-09-14
HK1219479A1 (zh) 2017-04-07
ZA201602054B (en) 2019-06-26
US20220348578A1 (en) 2022-11-03
CA3110803C (en) 2022-09-27
CA2926071C (en) 2021-11-09
AU2014332960B2 (en) 2018-03-29
WO2015053297A1 (ja) 2015-04-16
CN105612159A (zh) 2016-05-25
JP6995810B2 (ja) 2022-01-17
NZ757222A (en) 2021-12-24
MX361659B (es) 2018-12-13
EP3613740A1 (en) 2020-02-26
IL244969A0 (en) 2016-05-31
KR102388529B1 (ko) 2022-04-20
JP7182677B2 (ja) 2022-12-02
US20200181143A1 (en) 2020-06-11
US20250059191A1 (en) 2025-02-20
US12221443B2 (en) 2025-02-11
EP3299370B1 (en) 2021-11-24
EP3299370A1 (en) 2018-03-28
SG11201602723RA (en) 2016-05-30
IL289275B2 (en) 2023-02-01
AU2014332960A1 (en) 2016-05-26
US10604522B2 (en) 2020-03-31
ES2901198T3 (es) 2022-03-21
JP2021193107A (ja) 2021-12-23
EP3067355B1 (en) 2020-12-16
IL289275B (en) 2022-10-01
NZ743374A (en) 2021-12-24
MX383661B (es) 2025-03-14
TW201605855A (zh) 2016-02-16
KR20160065871A (ko) 2016-06-09
NZ719568A (en) 2018-06-29
US20190031659A1 (en) 2019-01-31
RU2695219C2 (ru) 2019-07-22
EP3067355A4 (en) 2017-04-26
RU2016116501A3 (cg-RX-API-DMAC7.html) 2018-07-12
DK3067355T3 (da) 2021-01-04
CA3110803A1 (en) 2015-04-16
MY199066A (en) 2023-10-12
CN111153903A (zh) 2020-05-15
US10131665B2 (en) 2018-11-20
AR132030A2 (es) 2025-05-21
MX2016004506A (es) 2016-06-16
AR097971A1 (es) 2016-04-20
US20160272641A1 (en) 2016-09-22
JPWO2015053297A1 (ja) 2017-03-09
AR132029A2 (es) 2025-05-21
HUE051925T2 (hu) 2021-04-28
EP3613741A1 (en) 2020-02-26
IL289275A (en) 2022-02-01
BR112016006266A2 (cg-RX-API-DMAC7.html) 2017-08-22
BR122022016622B1 (pt) 2023-11-07
HK1250030A1 (en) 2018-11-23
KR20220054694A (ko) 2022-05-03
KR102487297B1 (ko) 2023-01-12
US11414417B2 (en) 2022-08-16
JP2020007366A (ja) 2020-01-16
NZ757220A (en) 2021-12-24
AR132028A2 (es) 2025-05-21
NZ757221A (en) 2021-12-24
RU2019115119A3 (cg-RX-API-DMAC7.html) 2022-04-26
RU2019115119A (ru) 2019-05-29
BR112016006266B1 (pt) 2022-11-16
TWI673269B (zh) 2019-10-01
ES2842225T3 (es) 2021-07-13
IL244969B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP7182677B2 (ja) ジアザビシクロオクタン誘導体の結晶とその製造法
RU2838718C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2840014C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2847390C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2801220C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
HK40023145A (en) Preparation of a diazabicyclooctane derivative
HK40023146A (en) Preparation of a diazabicyclooctane derivative
HK40027891A (zh) 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
HK1226731A1 (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK1226731B (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191111

R150 Certificate of patent or registration of utility model

Ref document number: 6617029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250